MoonLake Immunotherapeutics
MLTX

$54.23

0.97%

Market Cap: $3.41B

About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Employees: 50

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

1% less funds holding

Funds holding: 111 [Q1] → 110 (-1) [Q2]

4% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 23

8% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 39

1.73% less ownership

Funds ownership: 99.64% [Q1] → 97.91% (-1.73%) [Q2]

10% less capital invested

Capital invested by funds: $3B [Q1] → $2.71B (-$293M) [Q2]

24% less call options, than puts

Call options by funds: $5.49M | Put options by funds: $7.23M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$62

14%

upside

Avg. target

$86

58%

upside

High target

$104

92%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 108 / 251 met price target	84%upside $100	Buy Reiterated	12 Sept 2024
Needham Serge Belanger 50% 1-year accuracy 56 / 112 met price target	14%upside $62	Buy Reiterated	12 Sept 2024
Needham Serge Belanger 50% 1-year accuracy 56 / 112 met price target	14%upside $62	Buy Maintained	8 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 108 / 251 met price target	84%upside $100	Buy Reiterated	1 Jul 2024
Oppenheimer Andreas Argyrides 74% 1-year accuracy 25 / 34 met price target	92%upside $104	Outperform Initiated	25 Jun 2024

See Analyst Rankings

Financial journalist opinion

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CET The event will provide business updates from MoonLake's CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). In addition, MoonLake will provide pipeline updates and details on additional catalysts for the 2024-2026 period, including for trials in new indications such as the Phase 2 trials of SLK in palmo-plantar pustulosis (PPP).

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026.

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, MoonLake's nanobody potentially offers better tissue penetration. Financially, MoonLake is secure with a cash runway for nearly seven years, preparing for Phase 3 trials without immediate funding needs.

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody ® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025 Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA) including unprecedented multi-domain responses across joints, skin and other domains, supporting potential best-in-class profile of sonelokimab Announced the imminent commencement of four additional clinical trials of sonelokimab across dermatology, and rheumatology, including innovative trials in palmo-plantar pustulosis (PPP), juvenile HS and seronegative spondyloarthritis Ended the first quarter with $547.1 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026 ZUG, Switzerland, May 7, 2024 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the first quarter of 2024. Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake's nanobody-based therapy in hidradenitis suppurativa (HS) and acti.

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Investors Business Daily

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

See News Rankings